E1 ReplicatedPreliminaryPEM not requiredRCTPeer-reviewedReviewed
Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study.
Young, Joel L · Psychiatry research · 2013 · DOI
Quick Summary
This study tested whether a medication called lisdexamfetamine (LDX), which affects brain chemicals related to focus and attention, could help people with ME/CFS who struggle with executive functioning—skills like planning, organizing, and decision-making. Twenty-six participants took either the medication or a placebo for 6 weeks, and those on LDX showed significantly better improvements in executive functioning, fatigue, and pain compared to placebo.
Why It Matters
Executive dysfunction (brain fog, difficulty with planning and organization) is a hallmark symptom of ME/CFS that significantly impairs daily functioning. This is one of the first controlled trials examining a dopaminergic medication for these deficits, offering a potential new pharmacological avenue and challenging the assumption that CFS is primarily a fatigue disorder.
Observed Findings
- Participants receiving LDX showed significantly greater improvement on the BRIEF-A executive functioning measure (21.38-point change) compared to placebo (3.36-point change).
- LDX-treated participants reported statistically significant reductions in fatigue relative to placebo.
- LDX-treated participants reported statistically significant reductions in generalized pain relative to placebo.
- The medication was tolerated at flexible daily doses of 30, 50, or 70 mg over the 6-week trial period.
Inferred Conclusions
- LDX may be a safe and efficacious treatment for executive functioning deficits in adults with CFS.
- Dopaminergic medications may play an important therapeutic role in addressing multiple symptoms of CFS, not just fatigue.
- Executive dysfunction in CFS may involve dysregulation of dopaminergic pathways that respond to stimulant medication.
Remaining Questions
- Do the executive functioning improvements observed at 6 weeks persist beyond the trial, or do benefits plateau and decline?
- Do improvements in executive functioning translate to meaningful gains in real-world activities of daily living and occupational/educational functioning?
- What is the optimal long-term dosing strategy, and are there subgroups of ME/CFS patients (e.g., by symptom profile or biomarkers) more likely to benefit?
What This Study Does Not Prove
This small 6-week study does not establish that LDX is a cure or long-term solution for ME/CFS; benefits observed over 6 weeks may not persist or generalize to the broader, more diverse ME/CFS population. The study does not clarify whether improvements in executive function translate to meaningful real-world functional gains or whether LDX addresses underlying disease mechanisms.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.